Search

Author/Creator Eichhorst, B.

1. BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G) AND VENETOCLAX (A) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2‐BAG TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG). (June 2017)

Authors:
Cramer, P.; von Tresckow, J.; Bahlo, J.; Robrecht, S.; Al‐Sawaf, O.; Langerbeins, P.; Engelke, A.; Fink, A.M.; Fischer, K.; Seiler, T.; von Weikersthal, L.Fischer; Hebart, H.; Kreuzer, K.A.; Ritgen, M.; Kneba, M.; Wendtner, C.M.; Stilgenbauer, S.; Eichhorst, B.; Hallek, M.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
25
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. CHARACTERISTICS, TREATMENT, AND OUTCOMES OF ≥ 80 YEAR OLD PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ENROLLED TO PROSPECTIVE TRIALS OF THE GERMAN CLL STUDY GROUP. (June 2017)

Authors:
Al‐Sawaf, O.; Bahlo, J.; Fischer, K.; Herling, C.; Bergmann, M.; Fink, A.M.; von Tresckow, J.; Langerbeins, P.; Cramer, P.; Stilgenbauer, S.; Wendtner, C.M.; Eichhorst, B.; Hallek, M.; Goede, V.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
99
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. FIXED‐DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES. (12th June 2019)

Authors:
Fischer, K.; Porro Lurà, M.; Al‐Sawaf, O.; Bahlo, J.; Fink, A.; Tandon, M.; Dixon, M.; Robrecht, S.; Warburton, S.; Humphrey, K.; Samoylova, O.; Liberati, A.M.; Pinilla‐Ibarz, J.; Opat, S.; Sivcheva, L.; Le Dû, K.; Fogliatto, L.M.; Utoft Niemann, C.; Weinkove, R.; Robinson, S.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
82
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORABMUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY Best abstract submitted by a young investigator / travel grant recipient. (12th June 2019)

Authors:
Tausch, E.; Bahlo, J.; Robrecht, S.; Schneider, C.; Bloehdorn, J.; Schrell, S.; Galler, C.; Al‐Sawaf, O.; Fink, A.; Eichhorst, B.; Kreuzer, K.; Tandon, M.; Humphrey, K.; Jiang, Y.; Schary, W.; Porro Lurà, M.; Döhner, H.; Fischer, K.; Hallek, M.; Stilgenbauer, S.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
84
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. HIGH EFFICACY OF VENETOCLAX PLUS OBINUTUZUMAB IN PATIENTS WITH COMPLEX KARYOTYPE (CKT) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PROSPECTIVE ANALYSIS FROM THE CLL14 TRIAL. (12th June 2019)

Authors:
Al‐Sawaf, O.; Lilienweiss, E.; Bahlo, J.; Robrecht, S.; Fink, A.; Patz, M.; Tandon, M.; Humphrey, K.; Jiang, Y.; Schary, W.; Porro Lurà, M.; Ritgen, M.; Tausch, E.; Stilgenbauer, S.; Eichhorst, B.; Fischer, K.; Hallek, M.; Kreuzer, K.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
104
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT‐NAÏVE EARLY STAGE CLL: PRIMARY ENDPOINT RESULTS OF THE PHASE 3 DOUBLE‐BLIND RANDOMIZED CLL12 TRIAL. (12th June 2019)

Authors:
Langerbeins, P.; Bahlo, J.; Rhein, C.; Gerwin, H.; Cramer, P.; Fürstenau, M.; Al‐Sawaf, O.; von Tresckow, J.; Fink, A.M.; Kreuzer, K.; Vehling‐Kaiser, U.; Tausch, E.; Müller, L.; Eckart, M.; Schlag, R.; Freier, W.; Gaska, T.; Balser, C.; Reiser, M.; Stauch, M.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
38
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS RECEIVING VENETOCLAX PLUS RITUXIMAB IN THE PHASE 3 MURANO STUDY. (12th June 2019)

Authors:
Wu, J.; Bolen, C.; Seymour, J.F.; Hillmen, P.; Eichhorst, B.; Eldering, E.; Kipps, T.J.; Langerak, A.W.; Mellink, C.; van der Kevie‐Kersemaekers, A.F.; Owen, C.; Chyla, B.; Punnoose, E.A.; Wang, J.; Boyer, M.; Humphrey, K.; Jiang, Y.; Kater, A.P.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
106
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. P641: RETREATMENT WITH VENETOCLAX AFTER VENETOCLAX, OBINUTUZUMAB +/- IBRUTINIB: POOLED ANALYSIS OF 13 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN GCLLSG TRIALS. (23rd June 2022)

Authors:
Cramer, P.; Fürstenau, M.; Giza, A.; Robrecht, S.; Tausch, E.; Schneider, C.; Wendtner, C.-M.; Hoechstetter, M.; Schetelig, J.; Böttcher, S.; Dreger, P.; Fink, A.-M.; Langerbeins, P.; Al-Sawaf, O.; Fischer, K.; Stilgenbauer, S.; Eichhorst, B.; Hallek, M.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
539
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. P663: HEALTH-RELATED QUALITY OF LIFE OUTCOMES ASSOCIATED WITH ZANUBRUTINIB VS IBRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (RR) CLL/SLL: RESULTS FROM THE RANDOMIZED PHASE 3 ALPINE TRIAL. (23rd June 2022)

Authors:
Hillmen, P.; Brown, J.; Lamanna, N.; O'Brien, S.; Tam, C.; Qiu, L.; Yang, K.; Barnes, G.; Wu, K.; Salmi, T.; Eichhorst, B.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
561
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. P671: TREATMENT SEQUENCES AND OUTCOMES OF PATIENTS WITH CLL TREATED WITH TARGETED AGENTS IN REAL-WORLD SETTINGS. (23rd June 2022)

Authors:
Mato, A. R.; Manzoor, B. S.; Coombs, C. C.; Lamanna, N.; Tuncer, H. H.; Brown, J. R.; Roeker, L. E.; Shadman, M.; Allan, J. N.; Ujjani, C.; Eichhorst, B.; Leslie, L.; Fleury, I.; Alhasani, H.; Rhodes, J.; Hill, B. T.; Barr, P. M.; Skarbnik, A.; Davids, M. S.; Bannerji, R.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
569
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗